A trial is underway that could be ‘the last roll of the dice’ for an HIV vaccine this decade

A novel trial that has been described as “the last roll of the dice” for a generation of HIV vaccines has entered its latter stages.

Called PrEPVacc, the trial is testing two vaccines alongside two forms of pre-exposure prophylaxis (PrEP) to test vaccine efficacy while offering protection to prevent the spread of HIV.

African-led and coordinated out of Entebbe, Uganda, with international support, its success could mark the start of a new phase of vaccine development. Should it fail, it could also see immunologists give up on a generation of vaccines.

Nearly 40 years since HIV was identified as the cause of AIDS, and 36 years since the first HIV vaccine trial, the medical community still does not have a working vaccine. Although antiretroviral treatments are well established, access varies. UNAIDS estimates 630,000 people died from AIDS-related illness globally in 2022, while 39 million people are living with HIV, including 1.3 million people newly infected last year.

The hope is that PrEPVacc will succeed where other trials have fallen short – most recently HVTN 702 (dubbed “Uhambo”), halted in February 2020, HVTN 705 (“Imbokodo”), discontinued in 2021 and HVTN 706 (“Mosaico”) in 2023, all of which were found to be safe but ineffective at preventing HIV.

Only one clinical trial, which took place in Thailand with results published in 2009, has been found to show modest effectiveness at preventing HIV infection. The efficacy of that vaccine, RV144, was about 30% (although the findings continue to be debated). For PrEPVacc to be considered a success, either of the two vaccines being tested will need to achieve an efficacy of at least 70%.

One vaccine combines pieces of synthetic HIV DNA with a protein base, while the other combines DNA, MVA (a weakened pox virus) and a protein base, like that used in RV144.

“This is an evolution (of RV144), not a revolution,” said Jonathan Weber, lead applicant and coordinator of PrEPVacc, and director of the Imperial College Academic Health Science Centre in London. “These are both regimens which have never gone into efficacy study before,” he added, describing the vaccines as “the best we feel, at the moment, that medical science can provide.”

The clinical trial began enrollment December 2020 and signed up the last of its 1,513 participants in March 2023. The participants are all between 18-40 years old and live in South Africa, Uganda or Tanzania.

All three countries have high rates of HIV/AIDS in adults, sitting within the top 15 countries in the world per 2021 estimates. But that is not necessarily why they were chosen to participate, said Eugene Ruzagira, PrEPVacc trial director.

Ruzagira is himself Ugandan, based in Entebbe at the Medical Research Council/Uganda Virus Research Institute, and oversees a team of researchers at trial sites in Durban, South Africa, Masaka, Uganda, and Dar es Salam and Mbeya, Tanzania. These locations, he explained, “had experience doing HIV prevention studies, not only vaccine trials, have established very good connections with the communities, and have the infrastructure we require.”

Though funding for PrEPVacc came from the European Union-sponsored EDCTP, “this genuinely needed to be an African study led by Africans and coordinated in Africa, where the data is analyzed in Africa and the laboratory work is done in Africa,” said Weber.

“It’s about time,” Ruzagira said. “We’ve had a few decades of preparation.”

Mark Runnacles/Getty Images

The world's first prosthetic toe dates to an Egyptian mummy. The Romans and the Greeks wrote about prosthetic arms and legs. But artificial limbs didn't gain a lot of movement and functionality until the 1500s, with hands that had the ability to grasp and legs that were able to kneel. While the technology continued to develop, the injuries of the Civil War would push Americans to the forefront of prosthetics. Today, technology is taking prosthetics to new levels: bionic limbs with natural feel, and built simply with 3-D printers.

FPG/Hulton Archive/Getty Images

People tried to inoculate themselves with smallpox as far back as 1,000 A.D. in China by scratching smallpox sores onto the skin. However, it wasn't until 1796 that English doctor Edward Jenner was able to use cowpox as a vaccine against the deadly disease. Vaccines would make another leap 50 years later, with the development of the hypodermic needle. Up until that point, a lancet had to be used. The needle was key to helping Louis Pasteur develop a successful rabies vaccine. By the 1920s, vaccines for diphtheria, tetanus, whooping cough and tuberculosis were available. By 1980, smallpox was eradicated from the world, and polio is almost eliminated from the planet.

Smithsonian National Museum of American History

While Galileo is frequently credited as the inventor of the thermometer, it wasn't until the mid-1800s (the era of the one pictured) that doctors were able to use thermometers to measure people's temperatures. Before that thermometers were not only large and cumbersome, but they also were not able to diagnose actual temperature grades. In 1866, a convenient 6-inch thermometer was invented. The early varieties were made of thin tubes of glass with mercury, and were mounted to ivory or wood.

Win McNamee/Getty Images

Plastic surgeons date the first nose job as far back as the 1400s, but developments in this area of surgery would have to wait until the practice of the skin graft was honed in the late 1800s. Even then, it would take another two centuries before doctors were able to apply this technology to transplanting parts of the face. French doctors did a partial facial transplant in 2005, and three years later, doctors at the Cleveland Clinic performed the world's first full facial transplant.

JEAN-SEBASTIEN EVRARD/AFP/Getty Images

Herbal mixtures using opium poppy were used as early as 4,000 B.C., but it wouldn't be administered intravenously until 1659 -- first delivered to a dog's vein using a goose quill. But in 1771, nitrous oxide was discovered, and in 1800, Humphry Davy wrote "as nitrous oxide in its extensive operation appears capable of destroying physical pain, it may probably be used with advantage during surgical operations in which no great effusion of blood takes place." It was first used for tooth extractions. By 1847, anesthetics were used for labor and other surgeries.

Haydn West/PA Wire/AP

One of the greatest life savers of our time, the seat belt reduces the probability of driving fatalities by about 50%. In the United States alone, it prevents about 15,000 deaths annually. The three-point seat belt, patented and introduced by Volvo in 1959, was filed under an open patent, making the technology available to any company, because the developers knew the kind of safety impact it could make. By 1968 all new cars in America had modern seat belts.

Joe Raedle/Getty Images

Aspirin is a remedy as old as time. Ancient Egyptians are known to have used willow bark to alleviate their aches and pains without knowing that it was salicylic acid, the natural version of aspirin, that reduced body temperature and inflammation. But it wasn't until the 19th century that a synthetic version of the acid was developed into the little pills we know today. In 1899 the pharmaceutical company Bayer handed out powdered versions of the acid to doctors, and by 1915, it was sold over the counter.

Hulton Archive/Getty Images

A scientific and social breakthrough, "the pill" allowed women to separate sex from procreation for the first time. It was such a controversial idea that the makers of Enovid, the first form of birth control submitted before the U.S. Food and Drug Administration, presented it as a treatment for severe menstrual disorders. Approved in summer 1957, it carried a warning: "This pill will likely prevent pregnancy." That year, an unusually large number of women had severe menstrual disorders.

ANNE-CHRISTINE POUJOULAT/AFP/Getty Images

The concept of stem cells, the idea of an original single cell acting as an ancestor for all organic beings, was first hypothesized in the late 19th century. But it wasn't until the 1950s that researchers found adult stem cells in bone marrow that could develop into different types of cells. This work led to the first human bone marrow transplant. It took another 40 years before human embryonic stem cells were derived, unleashing the potential for new drugs and therapies for a range of diseases like ALS, Alzheimer's, cancer and even blindness.

Keystone Features/Hulton Archive/Getty Images

The discovery of penicillin is considered a landmark in medical history, marking the beginning of antibiotic use. In 1928, Englishman Alexander Fleming discovered a strain of mold on some contaminated petri dishes: It was penicillin. It would be another decade before scientists understood the full potential of this mold. The challenge became scaling up production. American scientists lucked out when they found a strain of penicillin on a moldy cantaloupe at a Peoria, Illinois, grocery store. It grew 200 times as much as the strain Fleming found. Thanks to penicillin, the mortality rate of bacterial pneumonia fell from 18% during WWI to less than 1% in WWII.

Joe Raedle/Getty Images

Psychiatric drugs are a relatively new field, having just started development in the 1950s. Previously, psychiatrists stayed away from medications for treatment, using shock or psychotherapy instead. In fact, the first antipsychotic, chlorpromazine, was found by accident by surgeons trying to find a new sedative. It jump-started a new era of treating mental illness with medicine. While looking for a new therapy for schizophrenia, researchers discovered the first antidepressant.

STR/AFP/Getty Images

The first infant formula wasn't created until 1867. It was a liquid mixture of cow's milk and wheat and malt flour, cooked with potassium and called the "perfect infant food." By the late 1800s infant formulas were marketed, and in 1951 the first nonpowder formulas were introduced, and shortly thereafter formula became more popular than breast-feeding.

Sandy Huffaker/Getty Images/FILE

In 1944, U.S. researchers for the first time fertilized a human egg outside the womb. But keeping the egg alive was another matter. In the United States, a political battle over the morality of in vitro fertilization ensued. It was another three decades before the world's first "test-tube baby" was born. On July 26, 1978, Louise Joy Brown was born at a healthy 5 pounds, 12 ounces, a miracle for her parents, who suffered with years of infertility, and a miracle for science.

Daniel Acker/Bloomberg/Getty Images

Farmers have a long history of cross-breeding plants. However, once it was understood how to splice DNA and alter it in a plant, the technology was used to enhance certain traits in crops, making them more resistant to some pests and fortifying them with more nutrients. The first genetically modified food approved for human consumption by the Food and Drug Administration was the Flavr Savr tomato in 1994. It was modified to not get quickly squishy and thus survive transport with flavor and texture in tact. Soybeans are one of the most commonly modified plants. Today, the FDA is considering whether to approve genetically modified salmon, which can grow twice as fast as their nonmodified brethren.

Raphael GAILLARDE/Gamma-Rapho/Getty Images

James Watson and Francis Crick are the people most associated with discovering the double helix design of DNA, the hereditary building blocks of life, in 1953. However, many don't realize their discovery was built upon the work of British chemist Rosalind Franklin, who was able to use X-ray diffraction to produce photographic images of the molecule. While looking at her photographs, without her knowing, Watson and Crick made their discovery. It was another 50 years before the entire human genome was mapped.

Sean Gallup/Getty Images

While scientists tried organ transplants in humans and animals in the 18th century, the first successful organ transplant (skin, by the way) didn't occur until 1869. The next successful transplant wouldn't occur until the middle of the 20th century. The biggest boon to transplant technology was the development of the immunosuppressant drug Cyclosporine, which lessens the likeliness of rejection. The drug was approved by the U.S. Food and Drug Administration in 1983, and that same year the first lung transplant to last longer than six years took place. Today, every 10 minutes someone is added to the national transplant waiting list.

shutterstock

The first pacemakers were developed in the 1930s. They were large machines that were hand-cranked! Researchers worked on making smaller devices, and in 1958 the first human implanted device was created -- but it only lasted three hours. The pacemaker as we know it today wasn't achieved until the development of silicone transistors to improve the size of the machine, as well as the development of the long-life lithium battery. Today, pacemakers are about the size of a coin.

INDRANIL MUKHERJEE/AFP/Getty Images

Discovered accidentally by German physicist Wilhelm Conrad Röntgen, X-rays allowed doctors to see inside the human body for the first time without the use of surgery. They were used during the Balkan War to locate bullets and broken bones in patients. While doctors and scientists were eager to use X-ray technology, they didn't understand how strong the effects of radiation could be. In 1904, Thomas Edison's assistant, who worked with X-rays daily, died of skin cancer. Today, the technology is widely used.

SAM PANTHAKY/AFP/Getty Images

Until the beginning of the 20th century the only therapy for cancer was surgery. But in the early 1900s the development of the X-ray led to a new and improved method of treatment. Not only could X-rays be used to help detect cancer, but also to get rid of it. The use of chemotherapy wasn't developed until World War II. The U.S. military was researching a number of chemicals related to mustard gas when researchers came across the compound nitrogen mustard -- which was found to work against cancer of the lymph nodes. It was used as a model for other cancer medicines, jump-starting the development of chemotherapy.

Combining a vaccine with PrEP

In the randomized trial, each participant receives four injections of either vaccine A or B or a saline placebo over a 48-week schedule, along with a course of PrEP taken daily until week 26, a fortnight after the third injection – the logic being that the immune response will peak around then, said Ruzagira.

The US Centers for Disease Control and Prevention estimates PrEP taken as prescribed reduces the risk of getting HIV from sex by about 99%, and among people injecting drugs by at least 74%. The PrEPVacc trial is distributing two forms of PrEP pills, Truvada or Descovy, and is testing if the newer Descovy has the same or better effectiveness among the trial cohort. (Descovy currently holds FDA approval for use by men but not women.) Evaluating the combination of a trial HIV vaccine and PrEP is a first, say organizers.

Luwano Geofrey was the first trial participant in Masaka, Uganda. “I felt this was a big project that needed our support as a community,” he told CNN, in an interview conducted in the Luganda language by a PrEPVacc community engagement officer.

“One of the things I liked most was that participants would have routine HIV counseling and testing, free condoms, PrEP and support and care,” he explained. “I live and work in (a) fishing community. Most times, we lack these services.”

PrEP has not achieved high usage levels in Africa, said Weber, describing “massive issues about access and uptake (and) acceptance of PrEP as a reasonable intervention.”

Social stigma can complicate matters. In Uganda, for instance, PrEP is still distributed by HIV clinics, said Ruzagira, and being seen to enter a well-known HIV clinic can put people off seeking the medication.

“What we always hoped was once people started PrEP, they would see that it was easy, it was tolerable, it was acceptable, and would continue using it as long as they were at risk,” said Weber.

After 26 weeks, trial participants are given the option to access PrEP from public health facilities, but not everyone is transitioning to long-term use, say organizers.

Geofrey said his PrEP use during the 26 weeks was not always consistent, and that afterward, he tried to secure the drug from a local facility, but “more often than not (it) ran out of stock.”

Such issues are not limited to Uganda. “I would say that PrEP uptake is not what we would like it to be,” said Nishanta Singh, principal investigator at the Verulam clinical research site in Durban, South Africa.

“But it’s something that the community and the general population is starting to learn about,” she added. “We are seeing an increase in PrEP uptake as the weeks of the trial go by. Obviously, it’s not optimal, but it’s a work in progress.”

The forecast for a successful vaccine

In Verulam, more than half of participants have already received all four injections. As with the other trial sites, participants are tested and receive counselling every four to eight weeks, and will be monitored until October 2024.

The trial team is blind to the data, which is processed by an Independent Data Monitoring Committee. The results of the trial are scheduled for release in the fourth quarter of 2024.

In the case of vaccine trials, no news can be good news. Trials can be halted by monitoring committees if early data indicates a lack of efficacy (as was the case with HVTN 702) but that has not yet been the case for PrEPVacc.

“This is indeed a good sign, however, it is possible that there have been very few infection events in this trial, given that PrEP use was also encouraged in all participants,” said Sharon Lewin, a professor of medicine at The University of Melbourne.

Lewin, also president of the International AIDS Society, is not associated with the PrEPVacc trial, and offered caution regarding the vaccines’ potential efficacy.

“I would predict that the DNA, MVA and protein vaccines won’t provide too much protection from HIV infection, based on what we know from prior studies,” she said, although she commended the integration of PrEP into the Africa-led study, noting, “it’s also fantastic to see the first Phase 3 vaccine trial funded from outside the US.”

Should one or both vaccines prove effective, further trials would be needed and would likely involve multiple international partners. Should it fall short, “it’s really back to basics,” said Weber. “There’s nothing else around which looks any better of this generation of vaccine products.”

“In this decade, it will be the last roll of the dice,” he added. “My prediction is there won’t be another efficacy study of an HIV vaccine until the 2030s.”

Lewin does not believe that will be the case, pointing to new and rapidly advancing science.

One approach undergoing early testing is germline targeting, in which a series of slightly different vaccines are administered, designed to stimulate B-cells into producing “broadly neutralizing antibodies.” These powerful but hard-to-elicit antibodies could potentially damage the HIV virus as it mutates in an attempt to escape them, scientists theorize.

And last summer, a Phase 1 trial began in the US and another in Rwanda and South Africa of multiple vaccines utilizing mRNA (messenger ribonucleic acid). mRNA instructs the body to create proteins which induce an immune response and has already been used successfully in two Covid-19 vaccines.

But for the PrEPVacc team and its participants, there’s no option but to hold tight until the end of 2024 and hope that the results will be better than for other trials. “I did my very first HIV vaccine trial in 1991,” recalled Weber. “I think that probably tells you all you need to know about the agony of the search.”

Geofrey recalled what the trial asked of him: being told he and his wife should not bear children during its run; her initial concern that the PrEP bottles he came home with meant he was being treated for HIV; the initial disinformation in his community that the study was introducing HIV to participants, rather than seeking to prevent it. “It takes a lot of courage and time to be part of a trial like this,” he reflected.

“I know if the vaccines being tested give us positive results, I will consider myself, other participants, and scientists as the heroes of this century.”